Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients

被引：1
|
作者：
Vivaldi, C. [1 ]
Vasile, E. [1 ]
Fornaro, L. [1 ]
Caparello, C. [1 ]
Musettini, G. [1 ]
Pasquini, G. [1 ]
Lencioni, M. [2 ]
Ricci, S. [2 ]
Falcone, A. [1 ]
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Oncol Med Osped 1, Pisa, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31278-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2362
引用
收藏
页码：S456 / S457
页数：2
相关论文
共 50 条
  • [21] Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study
    Viaud, Juliette
    Brac, Clemence
    Artru, Pascal
    Le Pabic, Estelle
    Leconte, Berengere
    Bodere, Anais
    Pracht, Marc
    Le Sourd, Samuel
    Edeline, Julien
    Lievre, Astrid
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 692 - 696
  • [22] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer
    Giuliani, Jacopo
    Bonetti, Andrea
    PANCREATOLOGY, 2019, 19 (02) : 325 - 330
  • [24] Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
    Cartwright, Thomas H.
    Arlen, Aimee Ginsburg
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy
    Batra, Atul
    Tang, Patricia A.
    Cheung, Winson Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : 519 - 525
  • [26] FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis
    Vienot, A.
    Chevalier, H.
    Bolognini, C.
    Gherga, E.
    Meurisse, A.
    Vernerey, D.
    Borg, C.
    Turpin, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
    Fornaro, Lorenzo
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Baldi, Giacomo Giulio
    Allegrini, Giacomo
    Salvatore, Lisa
    Cremolini, Chiara
    Cupini, Samanta
    Cortesi, Enrico
    Tuzi, Alessandro
    Granetto, Cristina
    Brunetti, Isa Maura
    Ricci, Sergio
    Falcone, Alfredo
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 71 - 76
  • [28] The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Boeck, Stefan
    Heinemann, Volker
    FUTURE ONCOLOGY, 2008, 4 (01) : 41 - 50
  • [29] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [30] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
12345